JPH08502167A - Hcvタンパク質の翻訳を制御するための方法および組成物 - Google Patents
Hcvタンパク質の翻訳を制御するための方法および組成物Info
- Publication number
- JPH08502167A JPH08502167A JP6509245A JP50924594A JPH08502167A JP H08502167 A JPH08502167 A JP H08502167A JP 6509245 A JP6509245 A JP 6509245A JP 50924594 A JP50924594 A JP 50924594A JP H08502167 A JPH08502167 A JP H08502167A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- hcv
- sequence
- region
- translation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.C型肝炎ウイルス(HCV)核酸からのHCVタンパク質の翻訳を制御す る方法であって、以下の工程: 天然に存在しない第1の核酸であって、HCV核酸の5’UT領域内にある センス鎖に相補的な配列を含有する第1の核酸を提供する工程、ここで、該第1 の核酸は、ヘアピン形成領域、ペスチウイルスホモロジーボックスIV領域、およ び完全長HCV RNAを切断してサブゲノムHCV RNAを形成する切断領域からなる群よ り選択される配列を含有する;および 該HCV核酸と該第1の核酸とを、該第1の核酸およびHCV核酸がハイブリ ダイゼーション産物を形成し得る条件下で接触させる工程、ここで、該ハイブリ ダイゼーション産物は該HCV核酸の翻訳レベルを変え得る;を包含する、方法。 2.前記第1の核酸が配列番号1の中から選択される配列と相補的な配 列を有する、請求項1に記載の方法。 3.前記第1の核酸に相補的な配列に作動可能に連結したプロモーター を含有する、天然に存在しない第2の核酸を転写する工程をさらに包含する、請 求項1に記載の方法。 4.前記第1の核酸がホスホロチオエート核酸アナログである、請求項 2に記載の方法。 5.前記第1の核酸が3’末端に連結したコレステロール分子をさらに 含有する、請求項1に記載の方法。 6.核酸の翻訳を増大する方法であって、該核酸とペスチウイルスホモ ロジーボックスIVの配列に対応する配列を有する核酸とを作動可能に連結して翻 訳され得るこれらの複合核酸を形成する工程、を包含する方法。 7.核酸の翻訳を増大する組成物であって、翻訳されるべき核酸に作動 可能に連結するための、ペスチウイルスホモロジーボックスIV領域の配列に対応 する配列を有する核酸を含有する、組成物。 8.C型肝炎ウイルス(HCV)核酸からのHCVタンパク質の翻訳を制御す るための組成物であって、HCVの5’UT領域内のセンス鎖にある配列に相補的な 配列を有する天然に存在しない第1の核酸を含有する、あるいは該相補的な配列 を有する核酸を転写して形成し得る、組成物: ここで該第1の核酸は、ヘアピン形成領域、ペスチウイルスホモロジーボック スIV領域、および完全長HCV RNAを切断してサブゲノムHCV RNAを形成する切断領 域からなる群より選択される配列を含有する。 9.前記第1の核酸が、配列番号1の中から選択される配列に対応する 配列を有する、請求項8に記載の組成物。 10.前記第1の核酸がホスホロチオエート核酸アナログである、請求 項8に記載の組成物。 11.前記第1の核酸が3’末端に連結したコレステロール分子をさら に含有する、請求項8に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95279992A | 1992-09-28 | 1992-09-28 | |
US07/952,799 | 1992-09-28 | ||
PCT/US1993/009200 WO1994008002A2 (en) | 1992-09-28 | 1993-09-28 | Methods and compositions for controlling translation of hcv proteins |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000295290A Division JP2001145494A (ja) | 1992-09-28 | 2000-09-27 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2005334993A Division JP2006075174A (ja) | 1992-09-28 | 2005-11-18 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2008066878A Division JP4191786B2 (ja) | 1992-09-28 | 2008-03-14 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2010004460A Division JP2010120950A (ja) | 1992-09-28 | 2010-01-12 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08502167A true JPH08502167A (ja) | 1996-03-12 |
JP4637972B2 JP4637972B2 (ja) | 2011-02-23 |
Family
ID=25493246
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50924594A Expired - Lifetime JP4637972B2 (ja) | 1992-09-28 | 1993-09-28 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2000295290A Withdrawn JP2001145494A (ja) | 1992-09-28 | 2000-09-27 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2005334993A Withdrawn JP2006075174A (ja) | 1992-09-28 | 2005-11-18 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2008066878A Expired - Lifetime JP4191786B2 (ja) | 1992-09-28 | 2008-03-14 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2010004460A Withdrawn JP2010120950A (ja) | 1992-09-28 | 2010-01-12 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000295290A Withdrawn JP2001145494A (ja) | 1992-09-28 | 2000-09-27 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2005334993A Withdrawn JP2006075174A (ja) | 1992-09-28 | 2005-11-18 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2008066878A Expired - Lifetime JP4191786B2 (ja) | 1992-09-28 | 2008-03-14 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
JP2010004460A Withdrawn JP2010120950A (ja) | 1992-09-28 | 2010-01-12 | Hcvタンパク質の翻訳を制御するための方法および組成物 |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0718400A3 (ja) |
JP (5) | JP4637972B2 (ja) |
AT (1) | ATE310817T1 (ja) |
AU (1) | AU5141993A (ja) |
CA (1) | CA2145290C (ja) |
DE (1) | DE69333914T2 (ja) |
DK (1) | DK0662128T3 (ja) |
ES (1) | ES2256837T3 (ja) |
WO (1) | WO1994008002A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012105686A (ja) * | 2004-10-01 | 2012-06-07 | Novartis Vaccines & Diagnostic Inc | 改変型の小さい干渉rna分子および使用方法 |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6586568B1 (en) | 1994-02-14 | 2003-07-01 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US6720166B2 (en) | 1994-02-14 | 2004-04-13 | Abbott Laboratories | Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use |
US6451578B1 (en) | 1994-02-14 | 2002-09-17 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US6558898B1 (en) | 1994-02-14 | 2003-05-06 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US6051374A (en) * | 1994-02-14 | 2000-04-18 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use |
US5843450A (en) * | 1994-02-14 | 1998-12-01 | Abbott Laboratories | Hepatitis GB Virus synthetic peptides and uses thereof |
US6156495A (en) * | 1994-02-14 | 2000-12-05 | Abbott Laboratories | Hepatitis GB virus recombinant proteins and uses thereof |
US5981172A (en) * | 1994-02-14 | 1999-11-09 | Abbott Laboratories | Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for their use |
WO1995030746A1 (en) * | 1994-05-10 | 1995-11-16 | The General Hospital Corporation | Antisense inhibition of hepatitis c virus |
ZA964446B (en) * | 1995-06-06 | 1996-12-06 | Hoffmann La Roche | Oligonucleotides specific for hepatitis c virus |
US5807670A (en) * | 1995-08-14 | 1998-09-15 | Abbott Laboratories | Detection of hepatitis GB virus genotypes |
US5709997A (en) * | 1995-08-14 | 1998-01-20 | Abbott Laboratories | Nucleic acid detection of hepatitis GB virus |
US5955318A (en) * | 1995-08-14 | 1999-09-21 | Abbott Laboratories | Reagents and methods useful for controlling the translation of hepatitis GBV proteins |
US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
AU8897698A (en) * | 1997-07-30 | 1999-02-22 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
CA2386180C (en) * | 1999-10-13 | 2010-03-09 | Immunex Corporation | Vectors and methods for recombinant protein expression |
RU2158139C1 (ru) * | 1999-11-04 | 2000-10-27 | Научно-исследовательский институт физико-химической медицины Минздрава РФ | Способ селективного уничтожения клеток (варианты) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU225068B1 (en) * | 1989-03-17 | 2006-05-29 | Chiron Corp | Process for producing diagnostics and vaccine of nanbh |
DE69223562T2 (de) * | 1991-08-27 | 1998-06-04 | Hoffmann La Roche | Verfahren und Reagenzien zum Nachweis von Hepatitis C |
JPH06311885A (ja) * | 1992-08-25 | 1994-11-08 | Mitsubishi Kasei Corp | C型肝炎ウイルス遺伝子に相補的なアンチセンス化合物 |
ATE202383T1 (de) * | 1992-09-10 | 2001-07-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren für die behandlung von mit hepatitis c viren assoziierten krankheiten |
-
1993
- 1993-09-28 JP JP50924594A patent/JP4637972B2/ja not_active Expired - Lifetime
- 1993-09-28 AU AU51419/93A patent/AU5141993A/en not_active Abandoned
- 1993-09-28 ES ES93922414T patent/ES2256837T3/es not_active Expired - Lifetime
- 1993-09-28 WO PCT/US1993/009200 patent/WO1994008002A2/en active IP Right Grant
- 1993-09-28 AT AT93922414T patent/ATE310817T1/de active
- 1993-09-28 DK DK93922414T patent/DK0662128T3/da active
- 1993-09-28 DE DE69333914T patent/DE69333914T2/de not_active Expired - Lifetime
- 1993-09-28 EP EP95118443A patent/EP0718400A3/en not_active Withdrawn
- 1993-09-28 EP EP93922414A patent/EP0662128B1/en not_active Expired - Lifetime
- 1993-09-28 CA CA002145290A patent/CA2145290C/en not_active Expired - Lifetime
-
2000
- 2000-09-27 JP JP2000295290A patent/JP2001145494A/ja not_active Withdrawn
-
2005
- 2005-11-18 JP JP2005334993A patent/JP2006075174A/ja not_active Withdrawn
-
2008
- 2008-03-14 JP JP2008066878A patent/JP4191786B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-12 JP JP2010004460A patent/JP2010120950A/ja not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012105686A (ja) * | 2004-10-01 | 2012-06-07 | Novartis Vaccines & Diagnostic Inc | 改変型の小さい干渉rna分子および使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2145290A1 (en) | 1994-04-14 |
AU5141993A (en) | 1994-04-26 |
ES2256837T3 (es) | 2006-07-16 |
JP2010120950A (ja) | 2010-06-03 |
DE69333914T2 (de) | 2006-08-10 |
JP4191786B2 (ja) | 2008-12-03 |
JP2001145494A (ja) | 2001-05-29 |
EP0662128A1 (en) | 1995-07-12 |
CA2145290C (en) | 2002-03-05 |
ATE310817T1 (de) | 2005-12-15 |
JP2006075174A (ja) | 2006-03-23 |
EP0718400A2 (en) | 1996-06-26 |
EP0718400A3 (en) | 1996-07-03 |
WO1994008002A2 (en) | 1994-04-14 |
DE69333914D1 (de) | 2005-12-29 |
JP4637972B2 (ja) | 2011-02-23 |
EP0662128B1 (en) | 2005-11-23 |
JP2008161201A (ja) | 2008-07-17 |
DK0662128T3 (da) | 2006-02-20 |
WO1994008002A3 (en) | 1994-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4191786B2 (ja) | Hcvタンパク質の翻訳を制御するための方法および組成物 | |
US6132966A (en) | Method and reagent for inhibiting hepatitis C virus replication | |
JP3316216B2 (ja) | 安定化外部ガイド配列 | |
US6057093A (en) | Methods and compositions for controlling translation of HCV proteins | |
EP0693126B9 (en) | Method for selective inactivation of viral replication | |
Hanecak et al. | Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes | |
Glenn et al. | Trans-dominant inhibition of human hepatitis delta virus genome replication | |
JP2000506731A (ja) | 短い外部ガイド配列 | |
Jeng et al. | A pseudoknot ribozyme structure is active in vivo and required for hepatitis delta virus RNA replication | |
JP2001525192A (ja) | C型肝炎ウイルス関連疾患を治療する組成物及び方法 | |
WO1997007224A1 (en) | Reagents and methods useful for controlling the translation of hepatitis gbv proteins | |
JPH11510361A (ja) | 内部開始rna翻訳の選択的阻止 | |
AU3757199A (en) | Chimeras of hepatitis c virus and bovine viral diarrhea virus | |
CA2158427C (en) | Methods and compositions for controlling translation of hcv proteins | |
AU644115B2 (en) | Ribozyme inhibitors | |
US20090203890A1 (en) | Hepatitis c antivirals | |
KR100490699B1 (ko) | 씨형 간염 바이러스의 아이알이에스 발현 세포에서만 선택적으로 유전자 활성을 유도하는 트랜스-스플라이싱 리보자임 | |
AU736470B2 (en) | RNase L activators and antisense oligonucleotides effective to treat RSV infections | |
MXPA96002770A (en) | Method and reagent to inhibit the replication of hepatiti virus | |
Groppelli | Functional Analyses of Novel Insect Virus IRES Elements |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070320 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070619 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070806 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070719 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070817 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070914 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20071120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080314 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20080424 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20080501 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090318 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090331 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090521 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090529 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091008 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100624 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100629 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100721 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100726 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100824 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101004 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20101125 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131203 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
EXPY | Cancellation because of completion of term |